Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has received a consensus recommendation of “Hold” from the seven analysts that are currently covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $4.49.
A number of research analysts have weighed in on the stock. Zacks Investment Research cut shares of Sunesis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, August 14th. ValuEngine upgraded shares of Sunesis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd.
SNSS stock opened at $1.84 on Monday. Sunesis Pharmaceuticals has a twelve month low of $1.80 and a twelve month high of $7.69. The firm has a market cap of $72.64 million, a price-to-earnings ratio of -1.27 and a beta of 1.84.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last posted its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.24) by $0.04. equities research analysts expect that Sunesis Pharmaceuticals will post -0.89 EPS for the current fiscal year.
Hedge funds have recently bought and sold shares of the business. Millennium Management LLC boosted its stake in shares of Sunesis Pharmaceuticals by 594.4% during the first quarter. Millennium Management LLC now owns 106,599 shares of the biopharmaceutical company’s stock valued at $290,000 after purchasing an additional 91,248 shares during the period. Spark Investment Management LLC purchased a new stake in shares of Sunesis Pharmaceuticals during the first quarter valued at $204,000. Finally, Wells Fargo & Company MN boosted its stake in shares of Sunesis Pharmaceuticals by 38.4% during the first quarter. Wells Fargo & Company MN now owns 64,367 shares of the biopharmaceutical company’s stock valued at $175,000 after purchasing an additional 17,853 shares during the period. Institutional investors and hedge funds own 43.81% of the company’s stock.
About Sunesis Pharmaceuticals
Sunesis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.
Further Reading: Understanding Average Daily Trade Volume
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.